Key facts
- Edinburgh Biosciences’s last known valuation is $11.5M (Apr 2025).
- It has raised $7.6M; the latest was Later Stage VC ($3.0M) in Apr 2025.
- Notable investors include Innovate UK, UK Research and Innovation, Haoguang, Highland Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Edinburgh Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Edinburgh Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Edinburgh Biosciences
Developer of a cataract treatment technology intended to provide an alternative to surgery with a non-invasive treatment. The company's device focuses light onto the affected lens, reducing opacity, and monitoring changes in the lens by measuring the light emitted from the protein aggregates when excited with ultraviolet rays, enabling businesses to have access to treat cataracts with light treatment and providing information on its effectiveness.
- Sector
- Healthcare
- HQ
- Grangemouth, United Kingdom
- Founded
- 2003
- Employees
- 9
- Website
- edinburghbiosciences.com/
- Ownership
- Privately Held (backing)
Edinburgh Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Edinburgh Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Edinburgh Biosciences in its N-PORT filings yet. We sweep new filings monthly.